Medicamen Organics logo

Medicamen Organics financials and balance sheet

NSE: MEDIORGPharmaceuticals & Biotechnology

Last close ₹24.55down ₹0.90 (3.54%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹25.45.

52-week range of traded prices to 23 Oct 2026
₹19.10Low, 12 Jun 2026₹38.00High, 23 Oct 2025
Market cap
₹37 Cr
P/E
Lossover the last 12 months
P/B
Shares changed
Dividend yield
Nonein the last 12 months
ROE
−13.7%
Debt to equity
0.50
Volume, NSE
2,000100.0% delivered

2 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Medicamen Organics annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹38 Cr, year to Mar 2025A loss in the year to Mar 2026, −₹4.02 Cr

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue23
  2. Operating expenses−27
  3. Operating profit−4.0
  4. Depreciation−0.6
  5. Other income+0.1
  6. Finance costs−0.7
  7. Profit before tax−5.3
  8. Tax+1.3
  9. Net profit−4.0

What the company owns

  • Plant, investments and other assets₹21 Cr
  • Receivables₹19 Cr
  • Inventory₹11 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Net worth₹29 Cr
  • Borrowings₹14 Cr
  • Owed to suppliers₹6 Cr
  • Other liabilities₹3 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Medicamen Organics half-yearly results

₹ croreMar 2025Filed 31 MayMar 2026Filed 29 May
Revenue from operations38.222.6
31.726.7
Materials and goods bought21.415.8
Operating profit before depreciation6.4−4.0
Operating margin16.9%−17.8%
Depreciation and amortisation0.60.6
Operating profit after depreciation5.8−4.6
Other income0.10.1
Finance costs0.50.7
Profit before tax5.4−5.3
1.4−1.3
Net profit4.0−4.0
Net margin10.6%−17.8%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2025Filed 31 MayMar 2026Filed 29 May
30.528.6
30.128.7
Share capital–12.2
Reserves–16.6
Belonging to outside owners of subsidiaries0.4−0.1
12.414.3
27.221.7
1.61.3
Total assets59.251.6
13.814.8
45.436.9
Net debt8.213.0
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2025Filed 31 MayMar 2026Filed 29 May
0.86−4.60
0.86−6.70
−5.17−2.04
Receivables−9.157.23
Inventories−1.35−3.03
Payables4.62−6.18
Other working capital0.71−0.07
Tax paid0.09−0.12
Interest paid0.000.71
Capital spending0.001.74
Free cash flow0.86−6.33
0.09−1.72
3.323.48
Dividends paid0.000.00
Shares issued3.100.47
Net change in cash4.27−2.83
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. Borrowings repaid is left blank for the year to Mar 2025: the line is filed below nought and is smaller than the rounding of its section's total, so the statement does not show which way it moved cash.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2025Filed 31 MayMar 2026Filed 29 May
Earnings per share₹3.67−₹3.41
Diluted earnings per share₹3.66−₹3.41
Book value per share₹25.75₹24.55
Shareholder yield−12.2%−1.8%
Market cap at the year end (₹ crore)25.425.7

Ratios

Consolidated, years to March.Medicamen Organics PE ratio and valuation

RatioMar 2025Filed 31 MayMar 2026Filed 29 May
Revenue growth–−40.7%
13.4%−13.7%
–−27.1 pts
From the net margin–−35.9 pts
From asset turnover–8.3 pts
From borrowing–0.6 pts
Return on capital employed13.7%−10.8%
Cash conversion21.2%–
Interest cover11.4–
Debt to equity0.410.50
Receivable days247300
Inventory days128243
Payable days199128
Cash conversion cycle, days175415
Working capital days252436
Asset turnover0.650.41
Assets per rupee of net worth1.971.88
Sales per rupee of plant3.781.76
Capital spending to depreciation0.002.81
Interest cover is left blank for the year to Mar 2026: operating profit after depreciation is a loss, and a loss covers no interest bill.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
−7.3%
Measure3 years
Return on equity, average−0.1%
Return on capital employed, average1.4%
Operating margin, average−0.5%
Net margin, average−3.6%
Asset turnover, average0.53
Cash conversion cycle, days, average295
Debt to equity, average0.45

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations−4.60
Cash from investing−1.72
Cash from financing3.48
Capital spending1.74
Dividends paid0.00
Shares issued for cash0.47
Borrowings raised1.05
Borrowings repaid0.89

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2025Mar 2026
Receivables growth less revenue growthOur threshold 0 percentage points–12.78
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–66.80
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–−6.85
Effective tax ratePublished threshold 17.16 per cent25.47–
Tax charged less tax paid, % of profitOur threshold 10 percentage points23.73–
A threshold marked as ours has no published figure; it is the line we read the check against.